Related Experiment Video

Updated: Apr 29, 2026

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy
07:40

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy

Published on: May 26, 2023

1.8K

Novel therapeutic strategies for cardioprotection

Joost P G Sluijter1, Gianluigi Condorelli2, Sean M Davidson3

  • 1Department of Cardiology, University Medical Center Utrecht, The Netherlands; ICIN, Netherlands Heart Institute, Utrecht, The Netherlands.

Pharmacology & Therapeutics
|May 20, 2014
PubMed

Insights

Novel strategies are needed to protect the heart from ischemia-reperfusion injury (IRI), a major cause of death from heart disease. This review explores new cardioprotective therapies targeting mitochondria, epigenetics, and more to reduce heart attack damage.

Area of Science:

  • Cardiovascular Medicine
  • Translational Medicine
  • Molecular Cardiology

Background:

  • Ischemic heart disease (IHD) remains a leading cause of global morbidity and mortality.
  • While acute myocardial infarction treatments have improved, early reperfusion paradoxically causes ischemia-reperfusion injury (IRI), leading to further myocardial damage.
  • Currently, no effective therapies exist to mitigate acute IRI.

Purpose of the Study:

  • To outline the pathophysiology of acute IRI.
  • To review promising novel therapeutic strategies for cardioprotection against IRI.
  • To discuss the potential for pharmacological targeting and clinical application of these strategies.

Main Methods:

  • Review of current literature on acute IRI pathophysiology.
  • Exploration of emerging cardioprotective strategies including mitochondrial function, epigenetics, circadian rhythms, immune modulation, microvesicles, growth factors, stem cell therapy, and gene therapy.
  • Analysis of therapeutic potential and clinical applicability.

Main Results:

  • Acute IRI is a significant complication of reperfusion therapy for myocardial infarction.
  • Several novel therapeutic avenues show promise for cardioprotection.
  • These include targeting mitochondrial function, epigenetic modifications, circadian clock regulation, immune responses, and utilizing cell-based or gene-based therapies.

Conclusions:

  • Effective cardioprotection against IRI is crucial for improving outcomes in IHD patients.
  • Emerging strategies targeting molecular and cellular pathways offer significant therapeutic potential.
  • Further research and clinical translation are needed to develop effective treatments for IRI.

Keywords:
CardioprotectionCircadian clockGrowth factorsIschemia–reperfusion injuryMicrovesiclesMitochondria

More Related Videos

Delivery of Cardioactive Therapeutics in a Porcine Myocardial Infarction Model07:20

Delivery of Cardioactive Therapeutics in a Porcine Myocardial Infarction Model

Published on: February 10, 2023

2.7K
Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

7.9K

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.8K
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
753
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
790
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
624
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
1.6K
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
444